Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Con

Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18

ID: 102091

(firmenpresse) - DENVER, CO -- (Marketwire) -- 01/09/12 -- (OTCBB: OMBP), a clinical-stage biopharmaceutical company, today announced that it will present at Noble Financial Capital Markets' Eighth Annual Equity Conference being held January 17 & 18 at the Hard Rock Hotel & Casino in Hollywood, Florida.

Dr. James Crapo, Omni Bio's chief executive officer, is scheduled to speak on Wednesday, January 18 at 1:30 p.m. Eastern time (11:30 a.m. Mountain time).

Conference and presentation details will be made available at the Omni Bio website at . An archived presentation will be available on the website for 30 days.



Omni Bio Pharmaceutical, Inc. () is a clinical-stage biopharmaceutical company that has licensed potential new indications for an existing FDA approved drug -- Alpha-1 antitrypsin (AAT). Omni Bio's core technology is based on issued patents and patent applications licensed from the University of Colorado Denver (UCD) and a privately held company, Bio Holding, Inc. Omni Bio's lead development program has been funding research and a human clinical trial to evaluate the effectiveness of AAT in the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of diabetes, transplant rejection and bacterial and viral disorders.

Omni Bio is also a significant investor in BioMimetix Pharmaceutical, Inc. (BioMimetix), a recently formed biopharmaceutical corporation. BioMimetix is the exclusive licensee of an issued patent held by Duke University, and intends to develop a new class of patented compounds for the treatment of various diseases including radiation toxicity during the treatment of cancer using radiation therapy.





Omni Bio Pharmaceutical, Inc.
Bob Ogden
Chief Financial Officer - Investor Relations
(720) 488-4708
Email -

WestMountain Asset Management

Steve Anderson - Public Relations




(970) 212-4770
Email -

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial Critical Outcome Technologies Inc. to Meet with Prospective Licensing Partners for COTI-2 at Biotech Showcase
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 09.01.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 102091
Anzahl Zeichen: 0

contact information:
Town:

DENVER, CO



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 193 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18"
steht unter der journalistisch-redaktionellen Verantwortung von

Omni Bio Pharmaceutical, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Omni Bio to Present at Biotech Showcase 2015 ...

FORT COLLINS, CO -- (Marketwired) -- 01/06/15 -- (OTC PINK: OMBP) ("Omni Bio"), an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today that the Company is s ...

Alle Meldungen von Omni Bio Pharmaceutical, Inc.



 

Werbung



Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z